Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, announced a proposed underwritten public offering of common stock or pre-funded warrants in lieu of common stock, together with accompanying warrants to purchase common stock. The securities will be issued separately but must be purchased together, with Canaccord Genuity acting as sole bookrunner. The net proceeds are intended to advance the clinical development of the company's investigational oral therapy buntanetap for Alzheimer's disease and Parkinson's disease, as well as for working capital and general corporate purposes.
The offering remains subject to market and other conditions, and there is no assurance regarding its completion, size, or terms. For investors, the announcement signals Annovis Bio's ongoing need to secure funding as it progresses buntanetap through late-stage trials. The company's ability to complete the offering on favorable terms could affect its financial position and the timeline for its clinical programs. Further details are available in the full press release at https://ibn.fm/Pw0m8.
Buntanetap is a once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The potential impact of this offering extends beyond the company: if buntanetap succeeds in clinical trials, it could offer a new treatment option for Alzheimer's and Parkinson's, diseases with significant unmet medical needs. For more information, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X.
The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS. The announcement was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides wire-grade press release syndication, including editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution to millions of followers, along with corporate communications solutions. These services help companies like Annovis Bio reach a wide audience of investors and journalists. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
